Patent ID: 8877894
Filing Date: 2014-11-04
Classification: A61K,A61P,C07K

Abstract:
1. Method for preparing a hypoallergen candidate for immunotherapy comprising the steps of: (a) altering monomer-monomer interface area of an allergenic polypeptide, wherein said monomer-monomer interface area is about or less than 850 Å (b) testing in vitro the altered polypeptide obtained from step (a) for ability to activate release of histamine or other mediators of an allergic reactions from human cells checking that a IgE antibody specific to said allergenic polypeptide still binds to the altered polypeptide obtained from step (a) to confirm that said allergenic polypeptide has a native-like structure and thus capability to prevent the crosslinking of the IgE-FcεRI complexes on a mast cell or basophile surface antibodies and immunogenic potential to develop protective IgG antibodies, wherein those altered polypeptides which do not activate histamine release or said other mediators or activate histamine release or said other mediators less than the parent polypeptide and which have said native-like structure are considered as hypoallergen candidates for immunotherapy.